Molecular pathways and therapeutic targets in lung cancer

Cites (263)

Items 201–261 of 261

1. Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
   Salt, Megan B., Bandyopadhyay, Sourav, McCormick, Frank · 2014 · Cancer Discovery
2. Runx3 Inactivation Is a Crucial Early Event in the Development of Lung Adenocarcinoma
   You‐Soub Lee, Jung-Won Lee, Juwon Jang, Xin‐Zi Chi, Jang‐Hyun Kim, Yinghui Li, Minkyu Kim, Da-Mi Kim, Byeung-Sub Choi, Eung‐Gook Kim et al. · 2013 · Cancer Cell
3. Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer
   Helen J. Ross, George R. Blumenschein, Joseph Aisner, Nevena Damjanov, Afshin Dowlati, Jennifer L. Garst, James R. Rigas, Michael Smylie, Habib Hassani, Kimberly E. Allen et al. · 2010 · Clinical Cancer Research
4. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
   Mark Agulnik, Nelson, Ziehr, J R Johnson · 2013 · OncoTargets and Therapy
5. Pluripotent Stem Cell Protein Sox2 Confers Sensitivity to LSD1 Inhibition in Cancer Cells
   Xiaoming Zhang, Fei Lu, Jing Wang, Feng Yin, Zhengshuang Xu, Dandan Qi, Xianhui Wu, Yuwen Cao, Weihua Liang, Yuqing Liu et al. · 2013 · Cell Reports
6. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
   Monika Ashok Davare, Anna Lena Saborowski, Christopher A. Eide, Cristina E. Tognon, Rebecca Lee Smith, Johannes Elferich, Anupriya Agarwal, Jeffrey W Tyner, Ujwal P. Shinde, Scott W. Lowe et al. · 2013 · Proceedings of the National Academy of Sciences
7. The Met pathway: master switch and drug target in cancer progression
   Massimiliano Mazzone, Paolo Maria Comoglio · 2006 · The FASEB Journal
8. The role of the c-Met pathway in lung cancer and the potential for targeted therapy
   Martin Sattler, Rifat Hasina, Mamatha M. Reddy, Tara C. Gangadhar, Ravi Salgia · 2011 · Therapeutic Advances in Medical Oncology
9. FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma
   Matthew R. Ramsey, Catherine Wilson, Benjamin Ory, Stephen Michael Rothenberg, William C. Faquin, Alea A. Mills, Leif William Ellisen · 2013 · Journal of Clinical Investigation
10. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
    Luping Lin, Saurabh Asthana, Elton Chan, Sourav Bandyopadhyay, Maria M. Martins, Victor R. Olivas, Jenny Jiacheng Yan, Luu Q. Pham, Mingxue Michelle Wang, Gideon E. Bollag et al. · 2014 · Proceedings of the National Academy of Sciences
11. Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial
    David Paul Carbone, Keyue Ding, Heinrich Röder, Julia Grigorieva, Joanna Roder, Ming‐Sound Tsao, Lesley Seymour, Frances A. Shepherd · 2012 · Journal of Thoracic Oncology
12. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
    F. Malchers, F. Dietlein, Jakob Schöttle, Xin Lu, L. Nogova, K. Albus, L. Fernandez-Cuesta, J. Heuckmann, O. Gautschi, J. Diebold et al. · 2014 · Cancer Discovery
13. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer
    Markus Borner, Pierre Brousset, Brigitte Pfanner-Meyer, Marisa Bacchi, Silvia Vonlanthen, Michel A. Hotz, H. J. Altermatt, Daniel Schlaifer, John C. Reed, Daniel C. Betticher · 1999 · British Journal of Cancer
14. Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer
    Scott Andrew Laurie, Glenwood D. Goss · 2013 · Journal of Clinical Oncology
15. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
    Alejandro Vázquez‐Martín, Sílvia Cufí, Cristina Oliveras‐Ferraros, Violeta Zenobia Torres-Garcia, Bruna Corominas-Faja, Elisabet Cuyàs, Rosa Bonavia, Joana Visa, Begoña Martı́n-Castillo, Enrique Barrajón‐Catalán et al. · 2013 · Scientific Reports
16. The promise of anti-ErbB3 monoclonals as new cancer therapeutics
    Luigi Aurisicchio, Emanuele Marra, Giuseppe Roscilli, Rita Mancini, Gennaro Ciliberto · 2012 · Oncotarget
17. Hedgehog signaling in small-cell lung cancer: Frequent in vivo but a rare event in vitro
    Janni Vestergaard, Mikkel Wandahl Pedersen, Nina Marie Pedersen, Christian Ensinger, Zeynep Tümer, Niels Tommerup, Hans Skovgaard Poulsen, Lars Allan Larsen · 2006 · Lung Cancer
18. Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
    Jonathan Wade Goldman, Isett Laux, Feng Chai, Ronald E. Savage, Dora Ferrari, Edward Graeme Garmey, Richard G. Just, Lee S. Rosen · 2012 · Cancer
19. Frequency of EGFR and KRAS Mutations in Japanese Patients with Lung Adenocarcinoma with Features of the Mucinous Subtype of Bronchioloalveolar Carcinoma
    Akito Hata, Nobuyuki Katakami, Shiro Fujita, Reiko Kaji, Yukihiro Imai, Yutaka Takahashi, Takashi Nishimura, Keisuke Tomii, Kyosuke Ishihara · 2010 · Journal of Thoracic Oncology
20. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)
    Dorota Dworakowska B, Ewa Jassem, Jacek Jassem, Brigitte Peters, Rafał Dziadziuszko, Maciej Żylicz, Joanna Jakóbkiewicz‐Banecka, Grażyna Kobierska‐Gulida, Amelia Szymanowska, Jan Skokowski et al. · 2003 · Lung Cancer
21. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
    Giulio Metro, Rita Chiari, Simona Duranti, Annamaria Siggillino, Matthias Joachim Fischer, Diana Giannarelli, Vienna Ludovini, Chiara Bennati, Luca Marcomigni, Alice Baldi et al. · 2012 · Lung Cancer
22. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non‐small cell lung cancer
    Haruhiko Nakamura, Hisashi Saji, Akihiko Ogata, Makoto Hosaka, Masaru Hagiwara, Norihito Kawasaki, Harubumi Kato · 2002 · International Journal of Cancer
23. Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503
    Joseph M. Amann, Ju‐Whei Lee, Heinrich Röder, Julie Renee Brahmer, Adriana González, Joan H. Schiller, David Paul Carbone · 2010 · Journal of Thoracic Oncology
24. The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
    Edward B. Garon, Richard S. Finn, Habib Hamidi, Judy Dering, Sharon L. Pitts, Naeimeh Kamranpour, Amrita J. Desai, Wylie Hosmer, Susan E. Ide, Emin Avşar et al. · 2013 · Molecular Cancer Therapeutics
25. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development
    Lore Decoster, Isabelle Wauters, Johan Vansteenkiste · 2011 · Annals of Oncology
26. Divergent Genomic and Epigenomic Landscapes of Lung Cancer Subtypes Underscore the Selection of Different Oncogenic Pathways during Tumor Development
    William Wirt Lockwood, Ian M. Wilson, Bradley P. Coe, Raj Chari, Larissa A. Pikor, Kelsie L. Thu, Luisa Maren Solis, Maria Ines Nunez, Carmen Behrens, John Yee et al. · 2012 · PLoS ONE
27. Targeted Disruption of the 3p12 Gene, Dutt1/Robo1 , Predisposes Mice to Lung Adenocarcinomas and Lymphomas with Methylation of the Gene Promoter
    Jian Xian, Alan Aitchison, Linda Bobrow, Gerard Corbett, Richard Pannell, Terence Howard Rabbitts, Pamela H. Rabbitts · 2004 · Cancer Research
28. Epigenetic inactivation of the RUNX3 gene in lung cancer
    Koji Sato, Yoshio Tomizawa, Hironobu Iijima, Ryusei Saito, Tamotsu Ishizuka, Takashi Nakajima, Masatomo Mori · 2006 · Oncology Reports
29. Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung
    Andrew Mark Brunner, Daniel Botelho Costa, Rebecca Suk Heist, Elizabeth P. Garcia, Neal Ian Lindeman, Lynette Marie Sholl, Geoffrey R. Oxnard, Bruce Evan Johnson, Peter S. Hammerman · 2013 · Journal of Thoracic Oncology
30. The Involvement ofNRF2in Lung Cancer
    Alison K. Bauer, Thomas Hill, Carla‐Maria Alexander · 2013 · Oxidative Medicine and Cellular Longevity
31. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas
    Il-Jin Kim, David Alan Quigley, Minh D. To, Patrick Pham, Kevin Lin, Brian Jo, Kuang‐Yu Jen, Dan J. Raz, Jae Hong Kim, Jian‐Hua Mao et al. · 2013 · Nature Communications
32. Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non–small-cell lung cancer
    Ming‐Sound Tsao, Ye Yang, Alexander Marcus, Geoffrey Liu, Lun-jun Mou · 2001 · Human Pathology
33. VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
    David Paul Carbone, J. Stuart Salmon, Dean D. Billheimer, Heidi Chen, Alan B. Sandler, Heinrich Röder, Joanna Roder, Maxim Tsypin, Roy S. Herbst, Anne S. Tsao et al. · 2009 · Lung Cancer
34. Genome-Wide Analyses of Nkx2-1 Binding to Transcriptional Target Genes Uncover Novel Regulatory Patterns Conserved in Lung Development and Tumors
    Jean‐Bosco Tagne, Sumeet Gupta, Adam C. Gower, Steven S. Shen, Saaket Varma, Meenakshi Lakshminarayanan, Yuxia X. Cao, Avrum E. Spira, Thomas L. Volkert, María I. Ramirez · 2012 · PLoS ONE
35. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer
    Sanjay Modi, Akihito Kubo, Herbert K. Oie, Amy B. Coxon, Ahad Rehmatulla, Frederic J. Kaye · 2000 · Oncogene
36. Interaction between MYC and MCL1 in the Genesis and Outcome of Non–Small-Cell Lung Cancer
    Thaddeus D. Allen, Chang‐Qi Zhu, Kirk D. Jones, Naoki Yanagawa, Ming‐Sound Tsao, J. Michael Bishop · 2011 · Cancer Research
37. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors
    Geoffrey Ira Shapiro, Stewart W. McCallum, Laurel M. Adams, Laurie Jill Sherman, Steve Weller, Suzanne Swann, Harold N Keer, Dale Miles, Thomas R Müller, Patricia Mucci LoRusso · 2012 · Investigational New Drugs
38. Role of MetMAb (OA-5D5) in c-MET active lung malignancies
    Mosmi Surati, Premal H. Patel, Amy Peterson, Ravi Salgia · 2011 · Expert Opinion on Biological Therapy
39. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer
    Tsuyoshi Ueno, Kazunori Tsukuda, Shinichi Toyooka, Midori Ando, Munenori Takaoka, Junichi Soh, Hiroaki Asano, Yuho Maki, Takayuki Muraoka, Norimitsu Tanaka et al. · 2011 · Lung Cancer
40. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Takashi Kobayashi, Tomonobu Koizumi, Toshihide Agatsuma, Masanori Yasuo, Kenji Tsushima, Keishi Kubo, Seiichiro Eda, Hiroshi Kuraishi, Shigeru Koyama, Tsutomu Hachiya et al. · 2012 · Cancer Chemotherapy and Pharmacology
41. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
    Bart A. Westerman, Sari Neijenhuis, Ankie Poutsma, Renske D.M. Steenbergen, Roderick H.J. Breuer, Monique Egging, Inge J. van Wijk, Cees B.M. Oudejans · 2002 · PubMed
42. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
    Trevor J. Pugh, Gwyn D. Bebb, Lorena Barclay, Margaret Sutcliffe, John Fee, Chris Salski, Robert N. O'Connor, Cheryl Ho, Nevin Murray, Barbara L. Melosky et al. · 2007 · BMC Cancer
43. Pten -Null Tumors Cohabiting the Same Lung Display Differential AKT Activation and Sensitivity to Dietary Restriction
    Natasha L. Curry, Mari A. Mino-Kenudson, Trudy G. Oliver, Ömer H. Yilmaz, Vedat O. Yilmaz, Jade Y. Moon, Tyler Jacks, David M. Sabatini, Nada Y. Kalaany · 2013 · Cancer Discovery
44. Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Chiara Lazzari, Anna Spreafico, Angela Bachi, Heinrich Röder, Irene Floriani, Daniela Garavaglia, Angela Cattaneo, Julia Grigorieva, Maria Grazia Viganò, Cristina Sorlini et al. · 2011 · Journal of Thoracic Oncology
45. Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
    Alessia Noto, Claudia De Vitis, Giuseppe Roscilli, Luigi Fattore, Debora Malpicci, Emanuele Marra, Laura Luberto, Antonio D’Andrilli, Pierpaolo Coluccia, Maria Rosaria Giovagnoli et al. · 2013 · Oncotarget
46. Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors
    Geoffrey Ira Shapiro, Stewart W. McCallum, Laurel M. Adams, Laurie Jill Sherman, Steve Weller, Suzanne Swann, Harold N Keer, Dale Miles, Thomas R Müller, Daniel C. Rabe et al. · 2015 · Investigational New Drugs
47. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy
    Klaus Junker, Ulf Stachetzki, Daniela Rademacher, Albert Linder, H.-N. Macha, Achim Heinecke, Klaus‐Michael Müller, Michael Thomas · 2004 · Lung Cancer
48. Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
    Gerald Steven Falchook, Aung Naing, David S. Hong, Ralph Zinner, Siqing Fu, Sarina Anne Piha-Paul, Apostolia Maria Tsimberidou, Sonia K. Morgan‐Linnell, Yunfang Jiang, Christel C. Bastida et al. · 2013 · Oncotarget
49. Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data
    Wei‐Xiang Qi, Qiong Wang, Yan-Ling Jiang, Yuanjue Sun, Lina Tang, Aina He, Daliu Min, Feng Lin, Zan Shen, Yang Yao · 2013 · PLoS ONE
50. Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms
    Sivan Sapoznik, Ohad Hammer, Rona Ortenberg, Michal Judith Besser, Tehila Ben-Moshe, Jacob Schachter, Gal Markel · 2012 · Clinical and Developmental Immunology
51. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528
    Oliver Pascal Gautschi, Anne‐Marie C. Dingemans, Susanne Crowe, Solange Peters, Heinrich Röder, Julia Grigorieva, Joanna Roder, Francesco Zappa, Miklos Pless, Martin Hugo Brutsche et al. · 2012 · Lung Cancer
52. A Tabulated Summary of Targeted and Biologic Therapies for Non–Small-Cell Lung Cancer
    Neeta Somaiah, Nathan G. Simon, George R. Simon · 2012 · Journal of Thoracic Oncology
53. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
    Makoto Sudo, Tan Min Chin, Seiichi Mori, Ngan Doan, JONATHAN W. SAID, Makoto Akashi, Harold Phillip Koeffler · 2013 · Cancer Chemotherapy and Pharmacology
54. Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
    Marie Cumberbatch, Ximing Tang, Garry J. Beran, Sonia Eckersley, Xin Wang, Rebecca P.A. Ellston, Simon Patrick Dearden, Sabina C. Cosulich, Paul D. Smith, Carmen Behrens et al. · 2013 · Clinical Cancer Research
55. What's going on DNAメチレーションは術後の再発を予測しうるか?--1期非小細胞肺がん例での検討[Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glockner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG 'DNA methylation makers and early recurrence in stage 1 lung cancer']
    純司 鶴谷 · 2009 · Mebio oncology
56. Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas
    Elena González‐Sánchez, Juan Martín‐Caballero, Juana María Flores, Javier Hernández‐Losa, Ma Ángeles Montero, Javier Cortés, Rosó Marés, Mariano Barbacid, Juan A. Recio · 2013 · PLoS ONE
57. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients With EGFR Wild-Type Non–Small-Cell Lung Cancer: The Never-Ending Story
    Francesco Gelsomino, Francesco Agustoni, Monica Niger, Marika Valota, Eva Regina Haspinger · 2013 · Journal of Clinical Oncology
58. Evolving Aspects of Mesothelioma Carcinogenesis: SV40 and Genetic Predisposition
    Michele Carbone, Harvey Ira Pass · 2006 · Journal of Thoracic Oncology
59. A Tabulated Summary of Targeted and Biologic Therapies for Non–Small-Cell Lung Cancer
    George R. Simon, Neeta Somaiah · 2013 · Clinical Lung Cancer
60. A Correction to the Research Article Titled: “Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer” by H. Yasuda, E. Park, C.-H. Yun, N. J. Sng, A. R. Lucena-Araujo, W.-L. Yeo, M. S. Huberman, D. W. Cohen, S. Nakayama, K. Ishioka, N. Yamaguchi, M. Hanna, G. R. Oxnard, C. S. Lathan, T. Moran, L. V. Sequist, J. E. Chaft, G. J. Riely, M. E. Arcila, R. A. Soo, M. Meyerson, M. J. Eck, S. S. Kobayashi, D. B. Costa
    2014 · Science Translational Medicine
61. Reply to F. Gelsomino et al
    Scott Andrew Laurie, Glenwood D. Goss · 2013 · Journal of Clinical Oncology